Ardelyx, Inc. (NASDAQ: ARDX) delivered robust fourth-quarter and full-year 2025 monetary outcomes, highlighting strong progress in its key product IBSRELA. Complete income for This autumn reached $125.3 million, surpassing analyst expectations, whereas full-year income climbed 22% to $407.3 million.4012
Monetary Highlights
The corporate reported IBSRELA internet product income of $86.6 million in This autumn 2025, marking 61% year-over-year progress and an 11% enhance from the prior quarter. XPHOZAH generated $27.8 million within the quarter. For the complete 12 months, IBSRELA income soared 73% to $274.2 million, whereas XPHOZAH contributed $103.6 million.40
Regardless of income good points, Ardelyx posted a full-year internet lack of $61.6 million, or $0.26 per share, in comparison with $39.1 million in 2024. Money reserves strengthened to $264.7 million by year-end.40
Product Momentum and Enterprise Replace
IBSRELA demonstrated sustained demand, with elevated prescribing and affected person engagement driving progress. XPHOZAH noticed year-over-year will increase in complete dispenses, significantly amongst non-Medicare sufferers. Ardelyx additionally secured U.S. Patent No. 12,539,299 for oral formulations of tenapanor, extending safety to 2042.40
2026 Outlook and Pipeline Progress
Ardelyx tasks IBSRELA income between $410 million and $430 million in 2026, concentrating on no less than 50% progress. XPHOZAH forecasts vary from $110 million to $120 million. The corporate launched the Section 3 ACCEL trial for tenapanor in power idiopathic constipation, with first affected person dosing in Q1 2026. Growth of next-generation NHE3 inhibitor RDX10531 advances towards IND submission in H2 2026.40
Mike Raab, President and CEO, acknowledged, “The outcomes we delivered in 2025 mirror our group’s arduous work and disciplined execution to carry our medicines to extra sufferers in want, underscored by important IBSRELA progress, elevated adoption of XPHOZAH and fast development of our scientific growth applications.”40
